本季度信息
根据公告，2025年度公司实现营收约6.86亿元，同比下降3.33%。经调整净利润（扣除非经常性损益后）为-1.84亿元，同比下降3,680.51%。公告显示，公司在报告期内持续加大研发投入，约为3.58亿元，占营收比重超过50%。研发费用的增加以及核心产品里葆多®价格调整，导致本期利润贡献明显下降，是公司整体业绩承压的主要原因。
业务分项
公司核心产品里葆多®（盐酸多柔比星脂质体注射液）在报告期内由于未能进入集采中选名单，采取了梯度下调市场零售价格等策略，直接影响了其利润贡献。同时，报告期内公司推动多项研发项目进入临床试验的阶段性进展，包括针对三阴乳腺癌和HER2低表达乳腺癌的抗体偶联药物（ADC）项目，进一步推动了整体研发布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.